Burke, J. M., Sharman, J., Anz, B., Zuniga, R., Tun, A., Wright, D., Jani, P., Biondo, J., Wu, M., Mun, Y., Chopra, V. S., Farighi, R., Bisneto, J. V., Budde, E., Flinn, I. (2025). Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study. Blood. https://doi.org/10.1182/blood-2025-228